Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodabe Amaria

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The American Journal of Managed Care|February 19, 2019
Finding the right combination for neoadjuvant therapy in high-risk, stage III melanomaRodabe Amaria, Mary Caffrey
Immunotherapy|November 19, 2011
Novel therapies in melanomaBenjamin Scheier, Rodabe Amaria, Karl Lewis, et al.
Advances in Experimental Medicine and Biology|December 30, 2004
Proprotein processing and pancreatic islet functionJohn Hutton, Christina Wasmeier, Rodabe Amaria, et al.
Journal for Immunotherapy of Cancer|February 29, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapyAllison Betof Warner, Omid Hamid, Krishna Komanduri, et al.
International Journal of Dermatology|November 21, 2017
Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockadeShakuntala H Mauzo, Michael T Tetzlaff, Kelly Nelson, et al.
Journal of Cutaneous Pathology|September 14, 2017
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patientsMichael T Tetzlaff, Amir A Jazaeri, Carlos A Torres-Cabala, et al.
Journal for Immunotherapy of Cancer|February 3, 2024
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe Amaria, Anne Knisely, David Vining, et al.
Journal for Immunotherapy of Cancer|April 19, 2019
Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisDaniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al.
Journal for Immunotherapy of Cancer|October 12, 2018
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisDaniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al.
Journal of the National Cancer Institute|December 22, 2017
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer ImmunotherapyJodi A McKenzie, Rina M Mbofung, Shruti Malu, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The American Journal of Managed Care|February 19, 2019
Finding the right combination for neoadjuvant therapy in high-risk, stage III melanomaRodabe Amaria, Mary Caffrey
Immunotherapy|November 19, 2011
Novel therapies in melanomaBenjamin Scheier, Rodabe Amaria, Karl Lewis, et al.
Advances in Experimental Medicine and Biology|December 30, 2004
Proprotein processing and pancreatic islet functionJohn Hutton, Christina Wasmeier, Rodabe Amaria, et al.
Journal for Immunotherapy of Cancer|February 29, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapyAllison Betof Warner, Omid Hamid, Krishna Komanduri, et al.
International Journal of Dermatology|November 21, 2017
Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockadeShakuntala H Mauzo, Michael T Tetzlaff, Kelly Nelson, et al.
Journal of Cutaneous Pathology|September 14, 2017
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patientsMichael T Tetzlaff, Amir A Jazaeri, Carlos A Torres-Cabala, et al.
Journal for Immunotherapy of Cancer|February 3, 2024
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe Amaria, Anne Knisely, David Vining, et al.
Journal for Immunotherapy of Cancer|April 19, 2019
Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisDaniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al.
Journal for Immunotherapy of Cancer|October 12, 2018
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisDaniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al.
Journal of the National Cancer Institute|December 22, 2017
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer ImmunotherapyJodi A McKenzie, Rina M Mbofung, Shruti Malu, et al.
Pageof 2